Investor Presentaiton
CTS Key Business Updates (Cont'd)
Real World Studies
We successfully reached multiple real-world study collaborations with an multi-national pharmaceutical company.
Research collaborations with universities and hospitals on real world studies has been further strengthened, including a 14th Five-Year Plan
national level project cooperation with the Chinese University of Hong Kong and a multi-center investigator-initiated trial with the Chongqing
Medical University
We have also introduced DCT technology and mode into our real-world study projects, using artificial intelligent follow-up tools and self-
developed e-Clinical Trial Patient Management system (eCPM), effectively improving subject compliance and the efficiency and accuracy of
self-reported data, and could potentially reduce the project cost by more than 40%
Vaccine Clinical Services
Provides the one-stop phase I-IV vaccine clinical research solution, service offerings including vaccine clinical trial design, DMSA, clinical trial
operation, electronic data capture and site management etc.
We successfully helped the first Chinese vaccine to obtain the clearance to conduct the phase I clinical trial in the United States
In the first half of 2023, we also supported multiple phase III protective efficacy research for innovative vaccines in Provincial CDC and hospitals in
China including chickenpox, RSV, S. aureus and therapeutic BCG etc.
As of June 30, 2023, our vaccine clinical service team has conducted 14 overseas COVID-19 vaccine projects, 8 of those are phase III pivotal clinical
studies, covering 17 countries across Asia-Pacific, Latin America, Europe, and Africa, and having enrolled a total of more than 150,000 subjects
ā Tigermed
16
16View entire presentation